1/5
04:05 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/21
09:44 am
fate
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky [Yahoo! Finance]
Low
Report
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky [Yahoo! Finance]
12/8
08:00 am
fate
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Low
Report
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
11/25
09:08 am
fate
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
fate
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Neutral
Report
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
11/13
08:30 am
fate
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
11/4
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/4
12:09 pm
fate
Fate Therapeutics (NASDAQ:FATE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Fate Therapeutics (NASDAQ:FATE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.
10/31
07:19 am
fate
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
Medium
Report
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
10/27
08:43 am
fate
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock.
High
Report
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock.
10/27
08:06 am
fate
Fate Therapeutics (NASDAQ:FATE) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
High
Report
Fate Therapeutics (NASDAQ:FATE) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
10/26
11:30 am
fate
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Medium
Report
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy